NexImmune priced shares at $17 to raise $110m in an upsized offering, enabling Amgen and Pfizer to exit the Johns Hopkins University spinout.
US-based cancer immunotherapy developer NexImmune raised $110m in an upsized initial public offering on the Nasdaq Global Market on Thursday, providing exits to pharmaceutical firms Amgen and Pfizer. The company issued nearly 6.5 million shares priced at $17, the top of its range, and shares closed at $25.33 on the first day of trading on…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.